ALKBH5 and glioblastoma: As shown in the survival analysis, only ALKBH5 acts as a risky factor in all the three GBM cohorts, the survival curves indicate that GBM patients with higher ALKBH5 expressions had a shorter survival time and rate (Fig. 3E–G).